Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition

Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.